173
Views
18
CrossRef citations to date
0
Altmetric
Original Article

A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD:the EXTEND Study

, , , , &
Pages 2251-2265 | Accepted 25 Aug 2006, Published online: 16 Oct 2006

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Svetlana Vyacheslavovna Morozova, Natalia Stepanovna Alekseeva, Sergey Vasilyevich Lilenko, Eduard Ivanovich Matsnev & Oleg Anatol’evich Melnikov. (2015) Effects and safety profile of betahistine in patients in the Russian contingent of OSVaLD, an open-label observational study in vestibular vertigo. International Journal of General Medicine 8, pages 47-53.
Read now
Ovidiu Băjenaru, Adina Maria Roceanu, Silviu Albu, Viorel Zainea, Alexandru Pascu, Mădălina Gabriela Georgescu, Sebastian Cozma, Luigi Mărceanu & Dafin Fior Mureşanu. (2014) Effects and tolerability of betahistine in patients with vestibular vertigo: results from the Romanian contingent of the OSVaLD study. International Journal of General Medicine 7, pages 531-538.
Read now
Serge Gauthier, Alain Robillard, Sharon Cohen, Sandra Black, John Sampalis, Diane Colizza, Frederica de Takacsy & Robyn Schecter. (2013) Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE study. Current Medical Research and Opinion 29:8, pages 989-1000.
Read now
Serge Gauthier, Angela Juby, William Dalziel, Bonita Réhel & Robyn Schecter. (2010) Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE). Current Medical Research and Opinion 26:5, pages 1149-1160.
Read now
Roberta Annicchiarico, Alessia Federici, Carla Pettenati & Carlo Caltagirone. (2007) Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life. Therapeutics and Clinical Risk Management 3:6, pages 1113-1123.
Read now

Articles from other publishers (13)

Xiang-Peng Kong, Hai-Qin Ren, Etta Y. L. Liu, Ka-Wing Leung, Shu-Chen Guo, Ran Duan, Tina T. X. Dong & Karl W. K. Tsim. (2020) The Cholinesterase Inhibitory Properties of Stephaniae Tetrandrae Radix. Molecules 25:24, pages 5914.
Crossref
Christos G. Theleritis, Kostas T. Siarkos & Antonios M. Politis. (2019) Unmet Needs in Pharmacological Treatment of Apathy in Alzheimer’s Disease: A Systematic Review. Frontiers in Pharmacology 10.
Crossref
Christos Theleritis, Kostas Siarkos, Everina Katirtzoglou & Antonios Politis. (2016) Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology 30:1, pages 26-49.
Crossref
Tae-Young HwangInn-Sook AhnSeonwoo KimDoh Kwan Kim. (2016) Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil. Psychiatry Investigation 13:3, pages 341.
Crossref
Kok Pin Ng, Aloysius Ng, Pryseley Assam, Esther Heng & Nagaendran Kandiah. (2014) Role of Cognitive Enhancer Therapy in Alzheimer’s Disease with Concomitant Cerebral White Matter Disease: Findings from a Long-Term Naturalistic Study. Drugs in R&D 14:3, pages 195-203.
Crossref
Gianfranco Spalletta, Carlo Caltagirone, Alessandro Padovani, Sandro Sorbi, Mahmood Attar, Delia Colombo & Luca Cravello. (2014) Cognitive and Affective Changes in Mild to Moderate Alzheimer’s Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A 6-Month Observational Study. PLoS ONE 9:2, pages e89216.
Crossref
Karen Berman, Henry Brodaty, Adrienne Withall & Katrin Seeher. (2012) Pharmacologic Treatment of Apathy in Dementia. The American Journal of Geriatric Psychiatry 20:2, pages 104-122.
Crossref
Fadi Massoud, Julie Eve Desmarais & Serge Gauthier. (2010) Switching cholinesterase inhibitors in older adults with dementia. International Psychogeriatrics 23:3, pages 372-378.
Crossref
Wei-Wei Zhang, Zu-Peng Xu, Yong-Yao Cui, Hao Wang, Ming-Ke Song, Juan Li, Bi-Yun Shao, Zheng Xia & Hong-Zhuan Chen. (2009) Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine. Journal of Neural Transmission 116:12, pages 1643-1649.
Crossref
Bernadette McGuinnessDavid Wilson, Stephen Todd & Peter Passmore. (2009) Effective use of drugs in Alzheimer's disease. Practice Nursing 20:Sup1, pages S11-S14.
Crossref
Jeffrey L. Cummings, Joan Mackell & Daniel Kaufer. (2008) Behavioral effects of current Alzheimer's disease treatments: A descriptive review. Alzheimer's & Dementia 4:1, pages 49-60.
Crossref
. (2007) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 22:7, pages 705-712.
Crossref
S. Gauthier, A. Juby, B. Rehel & R. Schecter. (2007) EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*. International Journal of Clinical Practice 61:6, pages 886-895.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.